# Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus

> **NCT00507793** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 385 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT00507793
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** —
- **Final completion:** 2002-06
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2007-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00507793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00507793, "Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00507793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*